RS20050333A - Proline derivatives having affinity for the calcium channel alpha-2- delta subunit - Google Patents
Proline derivatives having affinity for the calcium channel alpha-2- delta subunitInfo
- Publication number
- RS20050333A RS20050333A YUP-2005/0333A YUP20050333A RS20050333A RS 20050333 A RS20050333 A RS 20050333A YU P20050333 A YUP20050333 A YU P20050333A RS 20050333 A RS20050333 A RS 20050333A
- Authority
- RS
- Serbia
- Prior art keywords
- alkyl
- disorders
- alkylaminoc
- alkylaminosulfonyl
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Jedinjenja formule (I) ili njihove farmaceutski prihvatljive soli, solvati ili prolekovi, koja su derivati prolina korisni u lečenju epilepsije, nesvestice, hipokinezije, kranijalnog oboljenja, neurodegenerativnog oboljenja, depresije, anksioznosti, panike, bola, fibromalgije, artritisa, neuropatoloških oboljenja, poremećaja spavanja, visveralnog bola i gastrointestinalnih poremećaja. Takodje su opisani i postupci za dobijanje finalnog proizvoda i korisnih intermedijera. Opisani su i farmaceutski preparati koji sadrže jedno ili više jedinjenja. Gde je ili X, O, S, NH ili CH2 i Y je CH2 ili direktna veza, ili je Y, O, S ili NH, a X je CH2; i R je 3-12 člani cikloalkil, 4-12-člani heterocikloalkil, aril ili heteroaril, aril ili heteroaril, gde se svaki prsten može po potrebi supstituisati jednim ili više supstituenata nezavisno odabranim od halogena, hidroksi, cijano, nitro, amino, hidroksikarbonila, C1-C6alkila, C1-C6alkenila, C1-C6alinkila, C1-C6alkoksi, hidroksi C1-C6alkila, C1-C6alkoksi C1-C6alkila, perfluoro C1-C6alkila, perfluoro C1-C6alkoksi, C1-C6alkilamino, di- C1-C6alkilamino, amino C1-C6alkila, C1-C6alkilamino C1-C6alkila, di- C1-C6alkilamino C1-C6alkila, C1-C6acil, C1-C6aciloksi, C1-C6aciloksi C1-C6alkila, C1-C6acilamino, C1-C6alkiltio, C1-C6alkiltiokarbonil, C1-C6alkiltiokso, C1-C6alkoksikarbonil, C1-C6alkilsulfonil, C1-C6alkilsulfonilamino, aminosulfonil, C1-C6alkilaminosulfonil, di- C1-C6alkilaminosulfonil, 3-8-člani cikloalkil, 4-8člani heterocikloalkil, fenil i monociklični heteroaril; ili njihove farmaceutski prihvatljive soli, solvati ili prolekovi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0225379.7A GB0225379D0 (en) | 2002-10-31 | 2002-10-31 | Therapeutic proline derivatives |
| PCT/IB2003/004697 WO2004039367A1 (en) | 2002-10-31 | 2003-10-22 | Proline derivatives having affinity for the calcium channel alpha-2-delta subunit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS20050333A true RS20050333A (en) | 2007-06-04 |
Family
ID=9946940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YUP-2005/0333A RS20050333A (en) | 2002-10-31 | 2003-10-22 | Proline derivatives having affinity for the calcium channel alpha-2- delta subunit |
Country Status (39)
| Country | Link |
|---|---|
| EP (1) | EP1558246B1 (sr) |
| JP (2) | JP3940416B2 (sr) |
| KR (2) | KR100750782B1 (sr) |
| CN (1) | CN100418525C (sr) |
| AP (1) | AP2005003295A0 (sr) |
| AR (1) | AR041865A1 (sr) |
| AT (1) | ATE468116T1 (sr) |
| AU (1) | AU2003269411B2 (sr) |
| BR (1) | BR0315839A (sr) |
| CA (1) | CA2499698C (sr) |
| CO (1) | CO5550430A2 (sr) |
| CR (1) | CR7802A (sr) |
| DE (1) | DE60332646D1 (sr) |
| DK (1) | DK1558246T3 (sr) |
| EA (1) | EA009767B1 (sr) |
| EC (1) | ECSP055769A (sr) |
| ES (1) | ES2343624T3 (sr) |
| GB (1) | GB0225379D0 (sr) |
| GE (1) | GEP20074127B (sr) |
| GT (1) | GT200300234A (sr) |
| HK (1) | HK1081441A1 (sr) |
| HR (1) | HRP20050351A2 (sr) |
| IL (4) | IL167799A (sr) |
| IS (1) | IS7754A (sr) |
| MA (1) | MA27481A1 (sr) |
| MX (1) | MXPA05004662A (sr) |
| NL (1) | NL1024677C2 (sr) |
| NO (1) | NO330496B1 (sr) |
| OA (1) | OA12954A (sr) |
| PA (1) | PA8587201A1 (sr) |
| PE (1) | PE20040553A1 (sr) |
| PL (1) | PL376703A1 (sr) |
| RS (1) | RS20050333A (sr) |
| TN (1) | TNSN05122A1 (sr) |
| TW (2) | TW200416030A (sr) |
| UA (1) | UA81437C2 (sr) |
| UY (1) | UY28043A1 (sr) |
| WO (1) | WO2004039367A1 (sr) |
| ZA (1) | ZA200502305B (sr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0225379D0 (en) * | 2002-10-31 | 2002-12-11 | Pfizer Ltd | Therapeutic proline derivatives |
| US20050043345A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| WO2005097741A1 (en) * | 2004-04-05 | 2005-10-20 | Pfizer Limited | Process for the recrystallisation of proline derivates |
| WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| US7968733B2 (en) | 2006-06-06 | 2011-06-28 | Gifu University | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof |
| AR061728A1 (es) * | 2006-06-30 | 2008-09-17 | Pfizer Prod Inc | Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| CA2915517A1 (en) | 2013-06-26 | 2014-12-31 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. | Preparation method for pyrrolidine-2-carboxylic acid derivatives |
| WO2015003723A1 (en) * | 2013-07-12 | 2015-01-15 | Københavns Universitet | Substituted 4-proline derivatives as iglur antagonists |
| CN104418785A (zh) * | 2013-09-05 | 2015-03-18 | 浙江九洲药业股份有限公司 | 一种药物中间体的制备方法 |
| CN104829513B (zh) * | 2014-02-11 | 2019-02-19 | 浙江九洲药业股份有限公司 | 一种2-羧基-4-甲氧基甲基吡咯烷衍生物的制备方法 |
| CN104844495A (zh) * | 2015-06-05 | 2015-08-19 | 武汉理工大学 | 一种(2s,4s)-4-苯硫基-l-脯氨酸盐酸盐的合成方法 |
| TW202026281A (zh) * | 2018-12-12 | 2020-07-16 | 西班牙商艾斯提夫製藥股份有限公司 | 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物 |
| WO2020120606A1 (en) * | 2018-12-12 | 2020-06-18 | Esteve Pharmaceuticals, S.A. | New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions |
| EP3904339A1 (en) * | 2020-04-28 | 2021-11-03 | Esteve Pharmaceuticals, S.A. | Alkylaminoproline derivatives as alfa-2-delta-1 blockers |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4316906A (en) * | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
| CA1144930A (en) * | 1978-08-11 | 1983-04-19 | Miguel A. Ondetti | Mercaptoacyl derivatives of substituted prolines |
| US4311705A (en) * | 1980-10-06 | 1982-01-19 | E. R. Squibb & Sons, Inc. | Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines |
| ZA817601B (en) * | 1980-11-24 | 1982-10-27 | Squibb & Sons Inc | Carboxyalkyl amino acid derivatives of various substituted prolines |
| DE69231918D1 (de) * | 1991-04-19 | 2001-08-09 | Scios Nova Inc | Peptidantagonisten des bradykinin |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| CN1226929A (zh) * | 1996-08-02 | 1999-08-25 | 伊兰制药公司 | 电压门控钙通道拮抗剂和方法 |
| JP3196106B2 (ja) * | 1997-03-27 | 2001-08-06 | 参天製薬株式会社 | ロイコトリエンａ４ヒドロラーゼ阻害剤 |
| US6316638B1 (en) * | 1998-05-26 | 2001-11-13 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
| CO5300399A1 (es) * | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
| GB0225379D0 (en) * | 2002-10-31 | 2002-12-11 | Pfizer Ltd | Therapeutic proline derivatives |
-
2002
- 2002-10-31 GB GBGB0225379.7A patent/GB0225379D0/en not_active Ceased
-
2003
- 2003-10-22 OA OA1200500132A patent/OA12954A/en unknown
- 2003-10-22 UA UAA200504092A patent/UA81437C2/uk unknown
- 2003-10-22 DK DK03751192.0T patent/DK1558246T3/da active
- 2003-10-22 BR BR0315839-0A patent/BR0315839A/pt not_active IP Right Cessation
- 2003-10-22 RS YUP-2005/0333A patent/RS20050333A/sr unknown
- 2003-10-22 EP EP03751192A patent/EP1558246B1/en not_active Expired - Lifetime
- 2003-10-22 MX MXPA05004662A patent/MXPA05004662A/es active IP Right Grant
- 2003-10-22 CN CNB2003801024978A patent/CN100418525C/zh not_active Expired - Fee Related
- 2003-10-22 AP AP2005003295A patent/AP2005003295A0/xx unknown
- 2003-10-22 DE DE60332646T patent/DE60332646D1/de not_active Expired - Lifetime
- 2003-10-22 KR KR1020057007561A patent/KR100750782B1/ko not_active IP Right Cessation
- 2003-10-22 GE GEAP20038772A patent/GEP20074127B/en unknown
- 2003-10-22 CA CA002499698A patent/CA2499698C/en not_active Expired - Fee Related
- 2003-10-22 AT AT03751192T patent/ATE468116T1/de not_active IP Right Cessation
- 2003-10-22 KR KR1020077008828A patent/KR20070046213A/ko not_active Application Discontinuation
- 2003-10-22 WO PCT/IB2003/004697 patent/WO2004039367A1/en active Application Filing
- 2003-10-22 JP JP2004547896A patent/JP3940416B2/ja not_active Expired - Fee Related
- 2003-10-22 EA EA200500581A patent/EA009767B1/ru not_active IP Right Cessation
- 2003-10-22 ES ES03751192T patent/ES2343624T3/es not_active Expired - Lifetime
- 2003-10-22 PL PL376703A patent/PL376703A1/pl not_active Application Discontinuation
- 2003-10-22 AU AU2003269411A patent/AU2003269411B2/en not_active Ceased
- 2003-10-27 UY UY28043A patent/UY28043A1/es not_active Application Discontinuation
- 2003-10-28 GT GT200300234A patent/GT200300234A/es unknown
- 2003-10-29 PE PE2003001093A patent/PE20040553A1/es not_active Application Discontinuation
- 2003-10-29 AR ARP030103960A patent/AR041865A1/es not_active Application Discontinuation
- 2003-10-30 TW TW092130304A patent/TW200416030A/zh unknown
- 2003-10-30 TW TW095122538A patent/TW200633699A/zh unknown
- 2003-10-30 PA PA20038587201A patent/PA8587201A1/es unknown
- 2003-10-31 NL NL1024677A patent/NL1024677C2/nl not_active IP Right Cessation
-
2005
- 2005-03-17 IS IS7754A patent/IS7754A/is unknown
- 2005-03-17 NO NO20051407A patent/NO330496B1/no not_active IP Right Cessation
- 2005-03-18 ZA ZA200502305A patent/ZA200502305B/en unknown
- 2005-03-31 IL IL167799A patent/IL167799A/en not_active IP Right Cessation
- 2005-04-19 HR HR20050351A patent/HRP20050351A2/hr not_active Application Discontinuation
- 2005-04-21 CR CR7802A patent/CR7802A/es not_active Application Discontinuation
- 2005-04-22 CO CO05038508A patent/CO5550430A2/es not_active Application Discontinuation
- 2005-04-29 TN TNP2005000122A patent/TNSN05122A1/fr unknown
- 2005-04-29 MA MA28242A patent/MA27481A1/fr unknown
- 2005-04-29 EC EC2005005769A patent/ECSP055769A/es unknown
-
2006
- 2006-02-08 HK HK06101658A patent/HK1081441A1/xx not_active IP Right Cessation
- 2006-07-25 JP JP2006201384A patent/JP4555263B2/ja not_active Expired - Fee Related
-
2009
- 2009-11-05 IL IL201965A patent/IL201965A/en not_active IP Right Cessation
- 2009-11-05 IL IL201966A patent/IL201966A/en not_active IP Right Cessation
- 2009-11-05 IL IL201967A patent/IL201967A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS20050333A (en) | Proline derivatives having affinity for the calcium channel alpha-2- delta subunit | |
| PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
| AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
| UA100132C2 (en) | Isoxazolo-pyridine derivatives | |
| SE0104332D0 (sv) | Therapeutic agents | |
| HUP0400323A2 (hu) | Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HK1199444A1 (en) | Method of preparing 3,7-diamino-10h-phenothiazine compounds 3,7--10h- | |
| HUP0401783A2 (hu) | 3,4-Diszubsztituált ciklobutén-1,2-dionok mint CXC-kemokin receptor ligandumok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| DE60022328D1 (de) | Amid-derivate | |
| WO2009064747A3 (en) | 4(-3-(-2-(phenyl) morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl) benzenesulfon amide derivatives and related compounds as modulators of ion channels for the treatment of pain | |
| DK1480961T3 (da) | Glutaminylbaserede DPIV-inhibitorer | |
| MX2007002807A (es) | Compuesto 2-morfolino-4-pirimidona. | |
| BR0313968A (pt) | Derivados de heteroaril nitrila | |
| NO20024042D0 (no) | Aryl-fusjonerte azapolysykliske forbindelser | |
| RU2005117783A (ru) | 1, 5-диарилпиррол-3-карбоксамидные производные и их применение в качестве модуляторов каннабиноидных рецепторов | |
| WO2002074758A3 (en) | Novel amines as histamine-3 receptor ligands and their therapeutic applications | |
| NO20054361D0 (no) | Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte | |
| PE20030723A1 (es) | Derivados de heteroaril nitrilos como inhibidores de la catepsina k | |
| UA89067C2 (ru) | Производные гидантоина, полезные как ингибиторы металлопротеиназ | |
| AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester | |
| EA200500717A1 (ru) | Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат | |
| DK0732333T3 (da) | Indazolcarboxamider | |
| DK1333026T3 (da) | Fremgangsmåde til fremstilling af perindopril med höj renhed og nyttige mellemforbindelser til syntesen | |
| NO20071319L (no) | Fremgangsmate for fremstilling av isotiazolderivater. | |
| TW200514782A (en) | 5-substituted quinazolinone derivatives |